3.3734
price down icon9.07%   -0.3366
 
loading
Vaccinex Inc stock is traded at $3.3734, with a volume of 39,059. It is down -9.07% in the last 24 hours and up +25.41% over the past month. Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
See More
Previous Close:
$3.71
Open:
$3.7
24h Volume:
39,059
Relative Volume:
0.43
Market Cap:
$9.56M
Revenue:
-
Net Income/Loss:
$-22.01M
P/E Ratio:
-0.5111
EPS:
-6.6
Net Cash Flow:
$-18.31M
1W Performance:
-7.45%
1M Performance:
+25.41%
6M Performance:
-37.53%
1Y Performance:
-72.62%
1-Day Range:
Value
$3.37
$3.9499
1-Week Range:
Value
$3.04
$3.9499
52-Week Range:
Value
$1.39
$13.02

Vaccinex Inc Stock (VCNX) Company Profile

Name
Name
Vaccinex Inc
Name
Phone
585-271-2700
Name
Address
1895 MOUNT HOPE AVE, ROCHESTER, NY
Name
Employee
40
Name
Twitter
@Vaccinex
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
VCNX's Discussions on Twitter

Compare VCNX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
VCNX 3.37 9.56M 0 -22.01M -18.31M -6.60
VRTX 447.67 115.74B 10.63B -479.80M -1.35B 13.33
REGN 746.52 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 590.60 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.66 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.93 24.49B 3.30B -501.07M 1.03B 11.54

Vaccinex Inc Stock (VCNX) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-23-20 Downgrade BTIG Research Buy → Neutral
Sep-04-18 Initiated Ladenburg Thalmann Buy

Vaccinex Inc Stock (VCNX) Latest News

pulisher
Nov 18, 2024

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Vaccinex Reports Promising Alzheimer's Drug Data, Raises $8.35M Amid Financial Challenges | VCNX Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 15, 2024

Vaccinex Inc (VCNX) Quarterly 10-Q Report - Quartzy

Nov 15, 2024
pulisher
Nov 15, 2024

Vaccinex secures $2.15 million in private placement By Investing.com - Investing.com UK

Nov 15, 2024
pulisher
Nov 14, 2024

ARMISTICE CAPITAL, LLC Acquires Shares in Vaccinex Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 08, 2024

Latest Company News - Investing.com

Nov 08, 2024
pulisher
Nov 08, 2024

Vaccinex inks multiple antibody discovery deals using ActivMAb By Investing.com - Investing.com Canada

Nov 08, 2024
pulisher
Nov 07, 2024

Vaccinex inks multiple antibody discovery deals using ActivMAb - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC - GlobeNewswire

Nov 07, 2024
pulisher
Nov 07, 2024

Vaccinex Lands Major Pharma Deals: Amgen, Merck Partner on Breakthrough Antibody Tech | VCNX Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 06, 2024

Vaccinex Reports Improved Immunity Correlating with - GlobeNewswire

Nov 06, 2024
pulisher
Nov 05, 2024

VCNXVaccinex, Inc. Latest Stock News & Market Updates - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

Vaccinex's Pepinemab Breakthrough: New Data Shows Enhanced Cancer Immunotherapy Success | VCNX Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 01, 2024

Vaccinex reports progress in Alzheimer's treatment study By Investing.com - Investing.com Canada

Nov 01, 2024
pulisher
Nov 01, 2024

Vaccinex reports progress in Alzheimer's treatment study - Investing.com India

Nov 01, 2024
pulisher
Oct 31, 2024

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 - GlobeNewswire

Oct 31, 2024
pulisher
Oct 31, 2024

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain - Nasdaq

Oct 31, 2024
pulisher
Oct 28, 2024

Vaccinex stock tanks 40% despite positive Alzheimer’s study update - MSN

Oct 28, 2024
pulisher
Oct 25, 2024

Vaccinex Stock Spikes On 'Promising' Data On Alzheimer’s Drug Study: Retail Sentiment Brightens - Barchart

Oct 25, 2024
pulisher
Oct 24, 2024

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024 - GlobeNewswire

Oct 24, 2024
pulisher
Oct 20, 2024

Micron Technology (MU-Q) QuotePress Release - The Globe and Mail

Oct 20, 2024
pulisher
Oct 15, 2024

Orange Juice (OJX25) Quote - The Globe and Mail

Oct 15, 2024
pulisher
Oct 14, 2024

Antibody Library Technology Market Report to 2032 -AnaptysBio Inc, MorphoSys AG, XOMA Corporation, Abzena Plc, AvantGen – IndiaPolitics.com - IndiaPolitics.com

Oct 14, 2024
pulisher
Oct 09, 2024

Vaccinex faces potential Nasdaq delisting over equity shortfall - Investing.com India

Oct 09, 2024
pulisher
Oct 09, 2024

BTIG Research’s latest rating for VCNX stock - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

Vaccinex faces potential Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada

Oct 09, 2024
pulisher
Oct 09, 2024

Company’s Banking Shares: Up -90.42% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle

Oct 09, 2024
pulisher
Oct 09, 2024

Post-Trade Analysis: Vaccinex Inc (VCNX) Slides -27.92, Closing at 1.73 - The Dwinnex

Oct 09, 2024
pulisher
Oct 02, 2024

Vaccinex stock hits 52-week low at $2.98 amid market challenges - Investing.com

Oct 02, 2024
pulisher
Sep 25, 2024

Vaccinex stock hits 52-week low at $4.17 amid sharp annual decline - Investing.com Canada

Sep 25, 2024
pulisher
Sep 25, 2024

VSME’s price-to-free cash flow ratio: What it means for investors - US Post News

Sep 25, 2024
pulisher
Sep 25, 2024

Short Interest in Victory Square Technologies Inc. (OTCMKTS:VSQTF) Declines By 79.4% - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

Viemed Healthcare, Inc. (NASDAQ:VMD) Shares Purchased by Victory Capital Management Inc. - Defense World

Sep 25, 2024
pulisher
Sep 24, 2024

WUXI BIO Buys back ~3.32M Shrs for ~$42.55M Ytd - AASTOCKS.com

Sep 24, 2024
pulisher
Sep 24, 2024

Vaxcyte Inc (PCVX) receives a Buy rating from Mizuho - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Victrex plc (LON:VCT) Insider Jane Toogood Acquires 508 Shares - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Victrex Director Buys Shares, Signals Confidence - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

Bank of New York Mellon Corp Boosts Stock Holdings in Viemed Healthcare, Inc. (NASDAQ:VMD) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

StockNews.com Initiates Coverage on Vector Group (NYSE:VGR) - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

VICR Investors Have Opportunity to Lead Vicor Corporation Securities Fraud Lawsuit with the Schall Law Firm - Business Wire

Sep 23, 2024
pulisher
Sep 23, 2024

The Gross Law Firm Reminds Vicor Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 23, 2024VICR - PR Newswire

Sep 23, 2024
pulisher
Sep 23, 2024

Victory Capital Management Inc. Has $496,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Rhumbline Advisers Has $1.01 Million Position in V2X, Inc. (NYSE:VVX) - Defense World

Sep 23, 2024
pulisher
Sep 21, 2024

Choreo LLC Takes Position in Vector Group Ltd. (NYSE:VGR) - Defense World

Sep 21, 2024
pulisher
Sep 20, 2024

VICOR 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Vicor CorporationVICR - Business Wire

Sep 20, 2024
pulisher
Sep 20, 2024

VICR FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, - GlobeNewswire

Sep 20, 2024
pulisher
Sep 20, 2024

First Eagle Investment Management LLC Purchases 2,067 Shares of V2X, Inc. (NYSE:VVX) - Defense World

Sep 20, 2024
pulisher
Sep 20, 2024

Vaccinex issues new warrants, secures $6.2 million in funding - Investing.com

Sep 20, 2024
pulisher
Sep 20, 2024

Victory Capital Management Inc. Cuts Stake in Wyndham Hotels & Resorts, Inc. (NYSE:WH) - Defense World

Sep 20, 2024
pulisher
Sep 19, 2024

Vaccinex secures $6.2 million through warrant exercises By Investing.com - Investing.com Canada

Sep 19, 2024
pulisher
Sep 18, 2024

What's Going On With Vaccinex Stock Wednesday? - Benzinga

Sep 18, 2024

Vaccinex Inc Stock (VCNX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):